Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis

被引：43

作者：

Hou, Kelu ^{[1
]}

Yu, Zhiying ^{[1
]}

Jia, Yueping ^{[2
]}

Fang, Huihui ^{[3
]}

Shao, Shuai ^{[4
]}

Huang, Lin ^{[1
]}

Feng, Yufei ^{[1
]}

机构：

[1] Peking Univ, Dept Pharm, Peoples Hosp, 11 Xizhimen South St, Beijing 100044, Peoples R China

[2] Peking Univ, Dept Pediat, Peoples Hosp, Beijing 100044, Peoples R China

[3] Anhui Univ Sci & Technol, Affiliated Hosp 1, Huainan Peoples Hosp 1, Dept Pharm, Huainan 232001, Peoples R China

[4] Beihua Univ, Affiliated Hosp, Dept Pharm, Jilin 132011, Jilin, Peoples R China

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 152卷

关键词：

Diffuse large B-cell lymphoma; Ibrutinib; Meta-analysis; Non-Hodgkin's lymphoma; Single-arm; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; NERVOUS-SYSTEM LYMPHOMA; MULTICENTER PHASE-II; NON-HODGKIN-LYMPHOMA; ELDERLY-PATIENTS; R-CHOP; UNTREATED PATIENTS; SALVAGE THERAPY; PD-1; BLOCKADE; TRANSPLANTATION;

D O I：

10.1016/j.critrevonc.2020.103010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study aimed to evaluate the benefits and risks of patients with diffuse large B-cell lymphoma (DLBCL) treated with ibrutinib. PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov were searched for relevant studies. The pooled overall response (OR), complete response (CR), and partial response (PR) were 57.9 %, 35.0 %, and 20.1 %, respectively. The pooled OR and CR of ibrutinib monotherapy were 41.6 % and 15.2 % and of ibrutinib + rituximab-based therapy were 72.0 % and 47.5 %, respectively. The relapsed/refractory DLBCL achieved a pooled OR and CR of 49.7 % and 27.7 %, respectively. The pooled OR and CR were 64.2 % and 56.9 % in non-germinal center B-cell-like (non-GCB) DLBCL and 68.3 % and 36.0 % in relapsed/refractory central nervous system lymphoma (CNSL), respectively. The pooled median progression-free and overall survival were 4.54 months and 11.5 months, respectively. 70.7 % and 52.6 % patients experienced grade 3 adverse events and serious adverse events. The ibrutinib-contained therapy was well tolerated and showed the potential to improve tumor response of patients with non-GCB DLBCL and relapsed/refractory CNSL.

引用

页数：14

共 78 条

[1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[2]

[Anonymous], 2015, ADV METAANALYSIS STA

[3] Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study [J].

Ansell, Stephen M. ;

Minnema, Monique C. ;

Johnson, Peter ;

Timmerman, John M. ;

Armand, Philippe ;

Shipp, Margaret A. ;

Rodig, Scott J. ;

Ligon, Azra H. ;

Roemer, Margaretha G. M. ;

Reddy, Nishitha ;

Cohen, Jonathon B. ;

Assouline, Sarit ;

Poon, Michelle ;

Sharma, Manish ;

Kato, Kazunobu ;

Samakoglu, Selda ;

Sumbul, Anne ;

Grigg, Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (06) :481-+

[4] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[5] Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial [J].

Armand, Philippe ;

Nagler, Arnon ;

Weller, Edie A. ;

Devine, Steven M. ;

Avigan, David E. ;

Chen, Yi-Bin ;

Kaminski, Mark S. ;

Holland, H. Kent ;

Winter, Jane N. ;

Mason, James R. ;

Fay, Joseph W. ;

Rizzieri, David A. ;

Hosing, Chitra M. ;

Ball, Edward D. ;

Uberti, Joseph P. ;

Lazarus, Hillard M. ;

Mapara, Markus Y. ;

Gregory, Stephanie A. ;

Timmerman, John M. ;

Andorsky, David ;

Or, Reuven ;

Waller, Edmund K. ;

Rotem-Yehudar, Rinat ;

Gordon, Leo I. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (33) :4199-4206

[6] ESHAP Versus Rituximab-ESHAP in Frail Patients With Refractory Diffuse Large B-Cell Lymphoma [J].

Aviles, Agustin ;

Neri, Natividad ;

Huerta-Guzman, Judith ;

de Jesus Nambo, Maria .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (02) :125-128

[7] Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding:: A meta-analysis [J].

Bañares, R ;

Albillos, A ;

Rincón, D ;

Alonso, S ;

González, M ;

Ruiz-del-Arbol, L ;

Salcedo, M ;

Molinero, LM .

HEPATOLOGY, 2002, 35 (03) :609-615

[8] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[9] Guidelines for the management of diffuse large B-cell lymphoma [J].

Chaganti, Sridhar ;

Illidge, Tim ;

Barrington, Sally ;

Mckay, Pam ;

Linton, Kim ;

Cwynarski, Kate ;

McMillan, Andrew ;

Davies, Andy ;

Stern, Simon ;

Peggs, Karl .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (01) :43-56

[10] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

← 1 2 3 4 5 6 7 8 →